



Pfizer Inc. Announces Final Results of Exchange Offers

Friday, October 02, 2015 - 05:04am

Pfizer Inc. (“Pfizer”) (NYSE: PFE) announced today the final results of its previously announced offers to exchange any and all validly tendered and accepted notes of each series listed in the table below (collectively, the “Hospira Notes”) issued by Hospira, Inc., a recently acquired subsidiary of Pfizer, for new notes to be issued by Pfizer (collectively, the “Pfizer Notes”), and the related solicitations of consents to amend the indenture governing the Hospira Notes and the Hospira Notes (together, the “Exchange Offers”). A Registration Statement on Form S-4 (File No. 333-206758) (the “Registration Statement”) relating to the issuance of the Pfizer Notes was filed with the Securities and Exchange Commission (“SEC”) on September 3, 2015, was amended by Amendment No. 1 to the Registration Statement filed with the SEC on September 16, 2015, and was declared effective by the SEC on September 25, 2015.

As of 11:59 p.m., New York City time, on October 1, 2015 (the “Expiration Date”), the aggregate principal amounts listed in the table below of each series of Hospira Notes had been validly tendered and not validly withdrawn pursuant to the terms and conditions of the Exchange Offers. The final settlement of the Exchange Offers is expected to take place on or about October 5, 2015.

CUSIP No.

Series of

Hospira

Notes

to be

Exchanged

Aggregate

Principal

Amount

Outstanding

Tenders and

Consents

Received as

of the

Expiration

Date

Percentage

of Total

Outstanding

Principal

Amount of

such Series

of Hospira

Notes

441060AJ9

6.05%

Notes due

2017

\$550,000,000	\$502,779,000	91.41%	441060AM2
---------------	---------------	--------	-----------

5.20%

Notes due

2020

\$350,000,000	\$329,916,000	94.26%	441060AN0
---------------	---------------	--------	-----------

5.80%

Notes due

2023

\$350,000,000	\$342,017,000	97.72%	441060AL4
---------------	---------------	--------	-----------

5.60%

Notes due

2040

\$500,000,000	\$494,769,000	98.95%	
---------------	---------------	--------	--

The Exchange Offers were made pursuant to the terms and conditions set forth in Pfizer's prospectus, dated as of September 25, 2015 (the "Prospectus"), which forms a part of the Registration Statement, and the related Amended and Restated Letter of Transmittal and Consent (the "Letter of Transmittal") that contain the complete description of the terms and conditions of the Exchange Offers.

The dealer managers for the Exchange Offers were:

Citigroup Global Markets Inc.
390 Greenwich Street, 1st Floor

New York, New York 10013

Attention: Liability Management Group

(800) 558-3745 (toll free)

(212) 723-6106 (collect)

Goldman, Sachs & Co.
200 West Street

New York, New York 10282

Attention: Liability Management Group

(800) 828-3182 (toll free)

(212) 902-5183 (collect)

The exchange agent and information agent for the Exchange Offers is:

Global Bondholder Services Corporation 65 Broadway - Suite 404 New York, New York
10006 Attn: Corporate Actions Bank and Brokers Call Collect: (212) 430-3774 All Others,
Call Toll Free: (866) 470-3900

The proposals set forth in this message are subject to compliance with all local legal and regulatory obligations, including the obligation to inform and or consult with labor organizations, works councils, trade unions and employee representatives.

Contacts Pfizer Inc. Media: Joan Campion, 212-733-2798 201-761-9384 (M)
Joan.Campion@pfizer.com or Investor: Ryan Crowe, 212-733-8160 215-260-0914 (M)
Ryan.Crowe@pfizer.com